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Abstract
Background: Low plasma folate concentrations in pregnancy are associated with preterm birth. Here we show an
association between preconceptional folate supplementation and the risk of spontaneous preterm birth.
Methods and Findings: In a cohort of 34,480 low-risk singleton pregnancies enrolled in a study of aneuploidy risk,
preconceptional folate supplementation was prospectively recorded in the first trimester of pregnancy. Duration of
pregnancy was estimated based on first trimester ultrasound examination. Natural length of pregnancy was defined as
gestational age at delivery in pregnancies with no medical or obstetrical complications that may have constituted an
indication for delivery. Spontaneous preterm birth was defined as duration of pregnancy between 20 and 37 wk without
those complications. The association between preconceptional folate supplementation and the risk of spontaneous preterm
birth was evaluated using survival analysis. Comparing to no supplementation, preconceptional folate supplementation for
1 y or longer was associated with a 70% decrease in the risk of spontaneous preterm delivery between 20 and 28 wk (41
[0.27%] versus 4 [0.04%] spontaneous preterm births, respectively; HR 0.22, 95% confidence interval [CI] 0.08–0.61, p=0.004)
and a 50% decrease in the risk of spontaneous preterm delivery between 28 and 32 wk (58 [0.38%] versus 12 [0.18%]
preterm birth, respectively; HR 0.45, 95% CI 0.24–0.83, p=0.010). Adjustment for maternal characteristics age, race, body
mass index, education, marital status, smoking, parity, and history of prior preterm birth did not have a material effect on
the association between folate supplementation for 1 y or longer and spontaneous preterm birth between 20 and 28, and
28 to 32 wk (adjusted HR 0.31, 95% CI 0.11–0.90, p=0.031 and 0.53, 0.28–0.99, p=0.046, respectively). Preconceptional
folate supplementation was not significantly associated with the risk of spontaneous preterm birth beyond 32 wk. The
association between shorter duration (,1 y) of preconceptional folate supplementation and the risk of spontaneous
preterm birth was not significant after adjustment for maternal characteristics. However, the risk of spontaneous preterm
birth decreased with the duration of preconceptional folate supplementation (test for trend of survivor functions, p=0.01)
and was the lowest in women who used folate supplementation for 1 y or longer. There was also no significant association
with other complications of pregnancy studied after adjustment for maternal characteristics.
Conclusions: Preconceptional folate supplementation is associated with a 50%–70% reduction in the incidence of early
spontaneous preterm birth. The risk of early spontaneous preterm birth is inversely proportional to the duration of
preconceptional folate supplementation. Preconceptional folate supplementation was specifically related to early
spontaneous preterm birth and not associated with other complications of pregnancy.
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Preterm birth is the main cause of neonatal mortality and short-
and long-term morbidity. Neonatal mortality and morbidity are
inversely correlated with gestational age at delivery, with the
majority of those adverse outcomes associated with early preterm
birth (i.e., delivery before 32 wk gestation) [1]. As a consequence,
societal costs of preterm births in the US exceed US$26 billion a
year [1].
Unfortunately there are no effective methods of prevention or
treatment of preterm birth. The most promising intervention—
progesterone supplementation—to date has been shown to be
effective only in a small subset of women at risk for preterm birth
[2,3]: in women with prior preterm birth or with a short cervix
(#15 mm), constituting respectively 3.3% and 1.7% of pregnan-
cies at risk [4,5].
Several studies demonstrated an association between lower
concentrations of folate and shorter duration of pregnancy.
Observational studies have showed that women delivering preterm
have lower concentrations of folate in plasma or red blood cells [6–
9]. Results of interventional trials of folate supplementation during
pregnancy are less conclusive. Supplementation of folate during
pregnancy resulted in longer duration of pregnancy in some
[10,11] but not in all studies [12–14].
However, a growing body of evidence of human studies and
animal models suggests that duration of pregnancy may be the
ultimate consequence of conditions in the very earliest stages of
pregnancy or before conception [15–17]. We tested the hypothesis
that preconceptional folate supplementation is associated with
reduction in the risk of spontaneous preterm birth.
Methods
Study Population
In a secondary analysis of a previously described prospective
cohort study [18], we studied 34,480 women who delivered
singleton pregnancies between 20 wk 0 d and 42 wk 0 d. The
original Down syndrome screening study was conducted at 15 US
centers from October 1999 to December 2002 (Table S2). The
inclusion criteria were a maternal age of 16 y or older, singleton
live fetus, and a fetal crown–rump length corresponding to a
gestational age of 10 wk 3 d through 13 wk 6 d at enrollment.
Women were excluded from the study if they had undergone prior
measurement of nuchal translucency or if anencephaly was
diagnosed in the fetus.
Extensive information on patients’ demographics, medical and
obstetrical history, socioeconomic status measures, and exposures
during pregnancy were recorded. Copies of medical records were
reviewed in all cases where parents reported a possible neonatal
medical problem, in all Down syndrome screen–positive cases
without karyotype results, and in a 10% random sample of all
other enrolled cases by a single abstractor. Institutional review
board approval was obtained in all participating centers, and all
participants gave written informed consent.
Out of 42,367 patients approached, 38,033 patients were
enrolled. Of those enrolled 189 (0.5%) had missing data on folate
supplementation, 430 (1.1%) missing confounder data, 529 (1.4%)
gestational age at delivery .42 wk, 2,103 (5.5%) missing
gestational age at delivery, and 302 (0.8%) miscarried or aborted
pregnancy between enrollment and 20 wk. Complete data on
maternal characteristics, exposures, pregnancy complications, and
outcomes were available for 34,480 (91.4%) of the remaining
pregnancies.
Definition of Maternal Characteristics
Duration of consistent preconceptional folate supplementation,
with or without multivitamins, was self-reported in the first
trimester of pregnancy at the time of enrollment and patients were
followed until delivery. Duration of preconceptional folate
supplementation was reported as: ,1, 1–2, 3–4, 5–6, 7–11, and
.12 mo and was categorized into three groups: $1y ,,1 y, and
no preconceptional supplementation.
Maternal age was defined as maternal age at the time of birth
and categorized into ,35 and $35 y to reflect advanced maternal
age associated with increased risk of adverse pregnancy outcomes.
Race and ethnicity were self-reported by mother in the first
trimester of pregnancy. Maternal height and weight obtained in
the first trimester of pregnancy, respectively in cm and kg, were
included in calculation of body mass index. Body mass index was
categorized into three groups: ,20, 20–30, and .30. Maternal
education level was self-reported in total completed years of
education and categorized into #12 or .12 y. Marital status was
defined as married or not married. Both education and marital
status were used as measures of socioeconomic status. Smoking
was defined as a self-reported smoking status of the woman in the
first trimester. Prior preterm birth was defined as prior pregnancy
lasting less than 37 wk 0 d.
Definition of Preterm Birth
Duration of pregnancy in all women was based on ultrasound
measurement of crown–rump length in the first trimester. Preterm
birth was defined as duration of pregnancy between 20 wk 0 d and
36 wk and 6 d [1].
Spontaneous preterm birth was defined as preterm birth not
associated with medical or obstetrical complications constituting
indications for preterm delivery. Those indications included:
chromosomal abnormalities, structural malformations, stillbirth,
termination of pregnancy, pregnancy induced hypertension,
preeclampsia, chronic hypertension, gestational or pregestational
diabetes, placenta previa, and placental abruption.
Secondary Outcomes
Small for gestational age was an infant with birth weight below
the 10th percentile for gestational age [19]. Preeclampsia and
placental abruption were self-reported.
Statistical Analyses
Duration of preconceptional folate supplementation, catego-
rized $1y ,,1 y, and no supplementation, was compared across
maternal and obstetric characteristics. Univariate comparison of
continuous variables was performed using the Kruskal-Wallis test
and of categorical data using the Chi-square or Fisher exact tests.
All p-values are two-sided. Statistical significance is assumed at
p,0.05.
The risk of spontaneous preterm birth between the categories of
duration of preconceptional folate supplementation was compared
using time-to-event analysis. The gestational age from 20 wk
onward was used as the time scale. Gestational age at delivery
between 20 wk 0 d and 36 wk 6 d was taken as time of the event
in the absence of indications for delivery or as the time of
censoring in either their presence or if gestational age at delivery
was 37 wk 0 d or later. This approach allows assessment of the
variation in relative risk of spontaneous preterm birth with
gestational age.
The time to event data are presented as a cumulative
percentage of the event, as recommended for rare events [20].
Folate and Risk of Preterm Birth
PLoS Medicine | www.plosmedicine.org 2 May 2009 | Volume 6 | Issue 5 | e1000061The univariate comparisons were made using a log-rank test. The
crude and adjusted for maternal characteristics and risk factors for
preterm birth hazard ratios (HRs) were obtained using Cox
proportional hazard regression [21]. The risk of spontaneous
preterm birth was adjusted for maternal age, race and ethnicity,
body mass index in the first trimester of pregnancy, education,
marital status, smoking status, parity, and history of prior preterm
birth and recruitment center. The interaction terms between
duration of preconceptional folate supplementation and catego-
rized maternal characteristics and risks factors for preterm birth
were assessed using Cox proportional hazard regression and
multivariate logistic regression analyses. The proportional hazard
assumption was tested using global and specific tests to identify
categories of spontaneous preterm birth with constant HR [22].
The constancy of the log HR function was inspected visually, and
identified intervals of preterm birth were tested using the
proportional hazard assumption test of nonzero slope of the
scaled Schoenfeld residuals of time. Goodness of fit was assessed
using the test of Groennesby and Borgan [23]. Analysis of effect
modification was performed using interaction terms in the
proportional hazard regression and multivariable logistic regres-
sion for strata of each maternal characteristic adjusted for all other
characteristics. The association between duration of preconcep-
tional folate supplementation and the risk of preeclampsia,
placental abruption, and delivery of small for gestational age
infant were analyzed using multivariable logistic regression.
Statistical analyses were performed using Stata 10 (Stata, http://
www.stata.com/).
Table 1. Maternal characteristics and pregnancy outcomes in relation to preconceptional folate supplementation in 34,480
singleton pregnancies.
Characteristics Preconceptional Folate Supplementation p-Valuea
None ,1y $1y
n (% of total) 15,259 (44.3%) 12,444 (36.1%) 6,777 (19.6%) N/A
Age, y (median IQR) 27.8 (23.5–32.5) 31.1 (27.1–34.5) 33.1 (29.4–36.3) ,0.0001
BMI (median IQR) 24.5 (21.7–28.4) 23.3 (21.2–26.4) 23.2 (21.2–26.3) ,0.0001
Race/ethnicity, n (%)
White 7,672 (50.3) 9,931 (79.8) 5,906 (87.1) ,0.0001
Hispanic 5,674 (37.2) 1,501 (12.1) 386 (5.7) ,0.0001
Black 1,151 (7.5) 384 (3.1) 180 (2.7) ,0.0001
Asian 599 (3.9) 520 (4.2) 248 (3.7) 0.6
Native 95 (0.6) 73 (0.5) 37 (0.5) 0.5
Other 68 (0.5) 35 (0.3) 20 (0.3) 0.04
Marital status, n (%) ,0.0001
Not married 5,667 (37.1) 1,122 (9.0) 463 (6.8)
Married 9,592 (62.9) 11,322 (91.0) 6,314 (93.2)
Education, n (%) ,0.0001
#12 y 6,769 (44.3) 1,663 (13.4) 608 (9.0)
.12 y 8,496 (55.7) 10,781 (86.6) 6,169 (91.0)
Smoking status, n (%) 1,181 (7.8) 289 (2.3) 149 (2.2) ,0.0001
Obstetrical history, n (%)
Nulliparous 6,072 (39.8) 6,440 (51.8) 3,036 (44.8) ,0.0001
Parous with no prior preterm birth 8,040 (52.7) 5,290 (42.5) 3,276 (48.3) ,0.0001
Parous with one or more prior preterm births 1,147 (7.5) 714 (5.7) 465 (6.9) 0.002
Duration of pregnancy, d (IQR) 39.4 (38.6–40.3) 39.6 (38.6–40.3) 39.4 (38.6–40.3) 0.1
Birth weight, g (IQR) 3,345 (3033–3657) 3,375 (3062–3686) 3,375 (3061–3714) 0.0001
Preterm birth, n (%)
,37 wk 1,263 (8.3) 894 (7.2) 503 (7.4) 0.005
,32 wk 253 (1.7) 147 (1.2) 73 (1.1) ,0.0001
Spontaneous ,37 wk 790 (5.2) 558 (4.5) 310 (4.6) 0.017
Spontaneous ,32 wk 99 (0.7) 46 (0.4) 16 (0.2) ,0.0001
Nonspontaneous
b ,37 wk 473 (3.1) 336 (2.7) 193 (2.9) 0.2
Nonspontaneous
b ,32 wk 154 (1.0) 101 0.8) 58 (0.9) 0.2
PPROM ,37 wk 204 (1.3) 144 (1.2) 76 (1.1) 0.1
PPROM ,32 wk 61 (0.4) 34 (0.3) 11 (0.2) 0.002
aKruskal-Wallis test or test for trend as appropriate.
bNonspontaneous indicates preterm birth associated with complications of pregnancy constituting indications for delivery.
doi:10.1371/journal.pmed.1000061.t001
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In the study population of 34,480 women, preconceptional
folate supplementation was used by 6,777 (19.6%) for $1y ,b y
12,444 (36.1%) for ,1 y, and not at all by 15,259 (44.3%)
(Table 1). Preconceptional folate supplementation was positively
associated with maternal age, white race, being married, education
duration above 12 y, and nulliparity, whereas it was negatively
associated with body mass index, smoking, Hispanic and black
ethnicity and race, and prior birth at term or preterm (Table 1).
Preconceptional folate supplementation was associated with higher
birth weight and lower rates of spontaneous preterm birth before
32 and 37 wk and preterm premature rupture of the membranes
(PPROM) before 32 wk (Table 1).
A total of 2,660 women (7.7%) delivered prematurely before
37 wk, and 473 (1.4%) before 32 wk. Spontaneous preterm birth
occurred in 1,658 women (4.8%) before 37 wk and in 160 (0.5%)
before 32 wk (Table 1). The risk of spontaneous preterm birth
decreased with the duration of preconceptional folate supplemen-
tation (test for trend of survivor functions, p=0.01; Figure 1) and
was the lowest in women who used folate supplementation for a
year or longer.
The protective effect of folate supplementation decreased with
advancing gestational age (Figure 1). Compared to women without
preconceptional folate supplementation, women with a year or
longer of supplementation had 70% lower risk (0.27% and 0.04%,
respectively), and women with supplementation shorter than a
year had 50% (0.27% and 0.16%, respectively) lower risk of
spontaneous preterm birth between 20 and 28 wk (Table 2) in
unadjusted analysis. The crude risk of spontaneous preterm birth
between 28 and 32 wk was 50% and 30% lower, respectively, for
the two supplementation groups (0.38% and 0.18%; 0.38% and
0.23%, respectively). The risk of spontaneous preterm births
between 32 and 37 wk was not significantly different between the
folate supplementation groups (Table 2).
The proportional hazard assumption was violated for the
gestational age interval from 20 to 37 wk, indicating that the risk
of spontaneous preterm birth in relation to duration of folate
supplementationvariesduringthis interval (proportional hazardtest
p,0.0001 and p=0.006 for duration of folate supplementation for
more or less than a year, respectively). However, for gestational age
intervals 20 to 28 (20 wk 0 d to 27 wk 6 d), 28 to 32 (28 wk 0 d to
31 wk 6 d) and 32 to 37 wk (32 wk 0 d to 36 wk 6 d) risks of
spontaneous preterm birth were constant and proportional hazard
assumption was met (proportional hazard tests p.0.2 for all).
Hence, the preterm birth gestational age intervals evaluated in this
study were identified by testing proportional hazard assumption,
rather than selected arbitrarily and are the gestational age intervals
with constant hazard ratios for spontaneous preterm birth.
Duration of preconceptional folate supplementation was also
associated with significantly reduced risk of all preterm birth,
spontaneous or not, in a similar manner (test for trend of survivor
functions p=0.004). Thus there was a significant association between
duration of preconceptional folate supplementation and the risk of
preterm birth before 32 wk when pregnancies with complications
constituting indication for delivery were censored or not. However,
there was no significant association between duration of preconcep-
tional folate supplementation and the risk of non-spontaneous,
complicated by obstetrical or medical conditions, preterm birth.
The association between duration of preconceptional folate
supplementation and the risk of spontaneous preterm birth was
also significant when using originally reported categories of
duration of folate supplementation (,1, 1–2, 3–4, 5–6, 7–11,
and .12 mo). A gradient is evident with less than 1 year of
supplementation in the trend of survivor functions (test for trend of
survivor functions p=0.042) and proportion of spontaneous
preterm birth before 32 wk (test for trend p,0.0001) (Figure 2).
Adjustment for the range of characteristics (maternal age, body
mass index, race and ethnicity, educational level, marital status,
smoking, parity and history of prior preterm birth) had only a
minimal effect on the association between preconceptional folate
supplementation for year or longer and spontaneous preterm birth
at 20 to 28 wk and 28 to 32 wk. The adjustment for those
characteristics eliminated significant association between shorter
preconceptional folate supplementation for less than a year and
spontaneous preterm birth (Table 2).
Figure 3 depicts the gradient in association between folate
supplementation and risk of spontaneous preterm birth. There was
Figure 1. Cumulative risk of spontaneous preterm birth in relation to duration of preconceptional folate supplementation.
Folate=0*, no preconceptional folate supplementation; Folate ,1 yr*, preconceptional folate supplementation for less than a year; Folate .=1 yr*,
preconceptional folate supplementation for a year or longer. *Test for trend of survivor functions, p=0.01.
doi:10.1371/journal.pmed.1000061.g001
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duration of preconceptional folate supplementation for preterm
births between 20 and 28 wk and 28 and 32 wk. Duration of
preconceptional folate supplementation was not associated with the
risk of spontaneous preterm birth between 32 and 37 wk. The same
gradient in the effect of duration of preconceptional folate
supplementation on the risk of spontaneous preterm birth was
observed when the three groups of the duration of preconceptional
folate supplementation were coded as three levels of a single variable.
The risk of spontaneous preterm birth at 20 to 28 and 28 to 32 wk
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Figure 2. Risk of spontaneous preterm birth before 32 wk in
relation to duration of preconceptional folate supplementa-
tion. Proportion (mean 6 standard error) of spontaneous preterm
births before 32 wk in women with no preconceptional folate
supplementation and supplementation for ,1, 1–2, 3–4, 5–6, 7–11,
and .12 mo.
doi:10.1371/journal.pmed.1000061.g002
Figure 3. Relative risk of spontaneous preterm birth in relation
to duration of preconceptional folate supplementation. HRs
and 95% CIs for spontaneous preterm birth in women with
preconceptional folate supplementation for a year or longer ($)o r
less than a year (&), compared to women without preconceptional
folate supplementation – reference value (#), from Cox proportional
hazard regression. *Wald test for equality of hazard ratios, testing the
joint hypothesis that coefficients are equal to 0 and that they are equal
to each other [66]. SPTB, spontaneous preterm birth.
doi:10.1371/journal.pmed.1000061.g003
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tation (adjusted HR 0.61, 95% confidence interval [CI] 0.41–0.93;
p=0.021 and 0.72, 0.54–0.96, p=0.027, respectively). There was no
significantassociationwiththeriskofspontaneouspretermbirthat32
to 37 wk (adjusted HR 0.99, 95% CI 0.92–1.07, p=0.8).
There were no statistically significant interactions between
duration of preconceptional folate supplementation and any of the
maternal characteristics or risks factors for preterm birth in
predicting the risk of spontaneous preterm birth (Figure 4).
Additionally, in stratified analysis the point estimates of odds ratios
(ORs) did not show a pattern indicative of interaction across strata
of maternal characteristics and risk factors for preterm birth
(Figure 4).
Body mass index (BMI), being married, and more than 12 y of
education were associated with lower risk, while Hispanic
ethnicity, black or Asian race, nulliparity, and prior preterm birth
were associated with higher risk of spontaneous preterm birth
(Table 3). The effects of Hispanic ethnicity, black or Asian race,
nulliparity, and prior preterm birth were stronger for early
spontaneous preterm birth. Maternal age and smoking did not
have significant effects after adjustment for remaining character-
istics (Table 3).
There was no evidence of violation of the proportional hazard
assumption for each variable (p.0.05 for all) or globally for the
whole model (p=0.7). The goodness of fit test showed no evidence
of poor fit (p=0.5)
The proportion of the PPROM among folate supplementation
groups in women with spontaneous preterm birth before 32 wk
was not significantly different (20.0%, 41.3%, and 36.4%, p=0.3;
for folate supplementation for $1y , ,1 y, and no folate
supplementation, respectively).
There was no significant association between duration of
preconceptional folate supplementation and the risk of preeclamp-
sia or placental abruption. The risk of delivery of a small for
gestational age infant was not significant after adjustment for
maternal characteristics (Table 4).
Among patients excluded from analysis who had data on
preconceptional folate supplementation, folate was used by 521
(14.7%) for 1 y or longer and by 1,018 (28.6%) for less than 1 y,
and was not used by 1,827 (51.4%).
Discussion
Interpretation of the Key Findings
We have shown that preconceptional folate supplementation for
a year or longer is associated with a decreased risk of early
spontaneous preterm birth. The association is characterized by
strength, temporal relationship, biological gradient, nonsignificant
effect of confounders, consistency with other studies, and
biological plausibility.
Preconceptional folate supplementation for a year or longer was
associated with over a 70% reduction in the risk of spontaneous
preterm birth before 28 wk and 50% reduction of the risk of
spontaneous preterm birth between 28 and 32 wk.
The strength of the association was significantly weaker if folate
supplementation was shorter than a year. There was also a
significant trend of decreased risk of spontaneous preterm birth
across the original seven categories of duration of folate
supplementation. This indicates existence of a biological gradient
in the association between preconceptional folate supplementation
and the risk of spontaneous preterm birth.
The relationship between preconceptional folate supplementa-
tion and risk of spontaneous preterm birth could potentially be
confounded by risk factors for spontaneous preterm birth and
indications for preterm delivery. However, adjustment for the risk
factors for spontaneous preterm birth had a minimal effect on the
association. The change in the coefficients observed with
adjustment was 32% for spontaneous preterm birth between 20
and 28 wk and 26% for spontaneous preterm birth between 28
and 32 wk. The resulting reduction in the risk of spontaneous
preterm birth, due to adjustment, of 78% versus 69% or of 55%
versus 47%, respectively, is clinically of no material importance.
Pregnancies with indications for preterm delivery were
censored, contributing to the denominator, the number of
pregnancies at risk, but not included in the nominator, the
number of spontaneous preterm births at each gestational age time
point. Analysis without censoring showed a significant association
between preconceptional folate supplementation and lower risk of
all early preterm births. However, there was no significant
association between duration of folate supplementation and the
risk of nonspontaneous preterm birth.
There were no significant interactions between folate supple-
mentation and maternal charactersitics and risk factors for
preterm birth, indicating that this association is observed
regardless of risk factors for preterm birth. Although the
confidence intervals of some of the strata were large and crossed
unity due to a small size of the strata, the interaction terms of these
covariates and duration of folate supplementation, which do not
depend on the size of the strata, are not significant.
The findings of this study are consistent with prior observational
studies showing that women delivering prematurely have lower
folate concentrations in plasma or red blood cells than women
delivering at term [8,24–26]. The interventional trials of folate
Figure 4. Stratified analysis of association between preconcep-
tional folate supplementation $1 y and the risk of spontane-
ous preterm birth before 32 wk. ORs and 95% CIs of spontaneous
preterm birth before 32 wk for preconceptional folate supplementation
for $1 y, stratified for a given characteristic and adjusted for all other
maternal characteristics. p-Values are estimated for interaction terms
between duration of folate supplementation and given characteristic.
The OR for BMI ,18.5 could not be estimated, as there were no cases of
spontaneous preterm birth before 32 wk among women using folate
supplementation for $1 y and with BMI ,18.5. MA, maternal age; Educ,
completed years of education; PARA No PPTB, parous woman without a
history of prior preterm birth; PARA PPTB, parous woman with a history
of prior preterm birth.
doi:10.1371/journal.pmed.1000061.g004
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pregnancy in some [11,27] but not in all studies [28–30].
However, those trials evaluated folate supplementation during
pregnancy, most in the third trimester rather than preconception-
ally, and were of insufficient size to assess early preterm birth.
Trials of folate supplementation for prevention of neural tube
defects did not evaluate the risk of preterm birth and had similar
limitations [31–35]. However, since 1998 there has been a
compulsory fortification of flour and grains with folate in the US.
Thus all women enrolled in the study were exposed to mandatory
folate fortification of grains. The prevalence of singleton preterm
deliveries decreased after the compulsory fortification was
instituted [36]. However, the decline in the incidence of preterm
birth and neural tube defects was substantially less after
fortification was instituted than was expected from the clinical
trials [37,38]. This was attributed to insufficient amount of folate
supplementation provided by folate grain fortification.
A substantial body of evidence suggests that the association
between folate supplementation and spontaneous preterm birth
is biologically plausible. Spontaneous preterm birth, especially
at early gestation, is strongly associated with intrauterine
infection [39]. Impaired function of neutrophils and lympho-
cytes, and increased prevalence of bacteriuria in pregnancy (a
risk factor for preterm birth) are associated with low plasma
folate concentrations [40–42]. Moreover, in a randomized trial,
folate supplementation was shown to decrease markers of
inflammation during pregnancy [43]. Recent findings have also
shown an association between polymorphism or deletion in
folate-metabolizing genes and the risk of preterm birth [44,45].
Biological plausibility of intrauterine infection–mediated effect
of folate supplementation is also supported by lack of
association with late spontaneous preterm birth. Late sponta-
neous preterm birth is much less strongly associated with
intrauterine infection than is spontaneous preterm birth before
32 wk of pregnancy [46].
Limitations of the Analyses
Early spontaneous preterm birth is a devastating but rare
outcome. Thus the findings of this study are based on small
number of cases, and additional cases may change substantially
those estimates in either direction. This is reflected in their wide
confidence intervals. However, the estimates remain statistically
significant also using exact logistic and Poisson regressions
methods, which are accurate with rare outcomes (Table S1).
Table 3. Risk of spontaneous preterm birth in relation to maternal characteristics (n=34,480).
Characteristic
Preterm Birth
Gestational Age na Preterm Birth
Adjusted HR 95% CI p-Value
Age (1,322/337) 1.01 0.89–1.14 0.9
BMI (72/958/371/258) 0.93 0.87–0.99 0.02
Race/Ethnicity
White Reference
Hispanic 20–28 wk (21/41) 1.80 1.20–2.71 0.004
28–32 wk (37/62) 1.32 0.98–1.77 0.07
32–37 wk (309/1,189) 0.95 0.87–1.05 0.3
Black 20–28 wk (14/48) 3.00 1.94–4.65 ,0.0001
28–32 wk (9/90) 1.26 0.76–2.08 0.3
32–37 wk (96/1,402) 1.10 0.96–1.26 0.2
Asian 20–28 wk (5/57) 2.08 1.19–3.63 0.01
28–32 wk (3/96) 0.80 0.38–1.71 0.6
32–37 wk (60/1,438) 1.00 0.87–1.15 0.9
Married (409/1,250) 0.93 0.81–1.06 0.3
Education (502/1,157) 0.87 0.77–0.98 0.034
Smoking (1,561/98) 1.11 0.89–1.37 0.4
Obstetrical history
Nulliparous 20–28 wk (33/29) 2.37 1.31–3.31 0.005
28–32 wk (55/44) 2.38 1.55–3.74 ,0.0001
32–37 wk (694/804) 1.46 1.30–1.64 ,0.0001
Prior preterm birth 20–28 wk (13/49) 5.46 2.62–11.36 ,0.0001
28–32 wk (15/84) 4.10 2.22–7.58 ,0.0001
32–37 wk (288/1,210) 4.38 3.79–5.06 ,0.0001
HRs adjusted for maternal age, body mass index, race and ethnicity, educational level, marital status, smoking, parity, and history of prior preterm birth and
preconceptional folate supplementation. Categorical variables: age, ,35 (reference) versus $35 y; BMI ,18.5 (reference), 18.5–25, 25–30, .30; married, not married
(reference) versus married; education, #12 (reference) versus .12 y; smoking, nonsmoking (reference) versus smoking; nulliparous, nulliparous versus parous
(reference); prior preterm birth, no prior preterm birth (reference) versus prior preterm birth. Proportional hazard assumption was met for each characteristic
(proportional hazard test, p.0.05 for all).
an=Number of spontaneous preterm births in each category in order as above or for dichotomous categories in order yes no.
doi:10.1371/journal.pmed.1000061.t003
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relevant confounders have not been accounted for. Thus it is
conceivable that folate supplementation could be a marker of
healthy behavior. Such an alternative hypothesis is unlikely
because the association between folate supplementation and the
risk of spontaneous preterm birth is specific to spontaneous
preterm birth, is not affected by other markers of healthy behavior,
and depends on the length of supplementation in a similar fashion
to the effect of folate supplementation on other disorders observed
in randomized trials.
Preconceptional folate supplementation was associated specifi-
cally with the risk of early spontaneous preterm birth and not with
the risk of other complications of pregnancy, preeclampsia, small
for gestational age infant, placental abruption, or nonspontaneous
preterm birth. Markers of healthy behavior, maternal character-
istics associated with healthy behavior, maternal age, BMI,
education, marital status, and smoking minimally affected the
association between folate supplementation and the risk of
spontaneous preterm birth. If preconceptional folate supplemen-
tation were a mere marker of healthy behavior, adjustment for
other markers of healthy behavior would either eliminate or
significantly attenuate the observed association with the risk of
spontaneous preterm birth. In fact, in our study, adjustment for
markers of healthy behavior did not have a substantial effect.
Thus it is unlikely that unaccounted confounding could eliminate
observed associations because of the specificity of this association
with only early spontaneous preterm birth and because two
unaccounted confounders—markers of socioeconomic status or
healthy behavior—are strongly correlated with measured con-
founders [1]. Moreover, some of the confounders included in the
analysis may be on the mechanistic pathway of the folate effect.
Short interpregnancy interval and unintended pregnancy are
unlikely to confound the findings, because the association between
preconceptional folate supplementation and risk of spontaneous
preterm birth was significant also in nulliparous women and
largely independent of maternal age, race/ethnicity, marital status,
and education, known risk factors for unintended pregnancy [47].
Conversely, subfertility is associated with multiple complications of
pregnancy such as preeclampsia and delivery of small for
gestational age infant, which were not associated with folate
supplementation [48].
None of the above-mentioned observations is sufficient by itself
to exclude the existence of unaccounted confounders, such as
healthy behavior of women who use folate preconceptionally.
However, collectively they strongly support a nonspurious
association of preconceptional folate supplementation and the risk
of spontaneous preterm birth. Definitive support for this
hypothesis can be provided only by a randomized trial.
The importance of duration rather than dosage of folate
supplementation has been observed previously. Meta-analyses of
folate for prevention of neural tube defects or stroke did not show a
significant association between dosage of folate supplementation
and the strength of its effect [49,50]. Meta-analysis of randomized
controlled trials of folate supplementation in stroke prevention has
shown that an inverse relationship exists between the duration of
folate supplementation and the risk of stroke, and that duration
rather than dosage of folate supplementation is critical [51].
Finally, women who used folate supplementation preconcep-
tionally had a lower risk of spontaneous preterm birth than women
who did not use it, regardless of the unknown dosage and
frequency of their use.
Use of folate in a combination with other micronutrients could
potentiallyconfoundthefindings.However,a systematicreviewand
individual clinical trials have shown that supplementation with
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PLoS Medicine | www.plosmedicine.org 8 May 2009 | Volume 6 | Issue 5 | e1000061multiple micronutrients in pregnancy did not offer additional
benefit over folate and iron supplementation alone [52–54]. In fact,
supplementation with some micronutrients, such as vitamins C and
E, was associated with increased risk of low birth weight [55].
Supplementation with zinc has been associated with lower risk of
preterm birth [56]. However, this effect was observed primarily in
the studies of low-income women. Conversely, in this study, folate
supplementation was associated with a lower risk of spontaneous
preterm birth regardless of the markers of socioeconomic status.
Low zinc levels were also associated with placental abruption, a
relationship that was not evident in this study of folate supplemen-
tation [57]. Moreover, data suggest that adding zinc may negate the
beneficial effect of folate and iron on low birth weight [58,59].
Postconceptional folate supplementation also could not con-
found our findings. In the US 93% of women use postconceptional
folate supplementation and in a population with early onset of
prenatal care (as in this study) the rate is likely much higher [60].
Moreover, a systematic review of folate supplementation during
pregnancy has shown no significant effect on the risk of preterm
birth, duration of pregnancy, or birth weight [61].
Another limitation of this study is that preconceptional folate
supplementation was self-reported at enrollment in the first
trimester of pregnancy. However, self-reported folate intake from
supplements has been shown to correlate with serum folate
concentrations during pregnancy and was a reliable measure of
folate supplementation [62]. Additionally, duration of preconcep-
tional folate supplementation was reported prospectively, and its
rate is similar to that in the general population [63]. Although a
significant reduction in the risk of spontaneous preterm birth was
observed across the original categories of duration of folate
supplementation, we analyzed larger categories, that are consistent
with other studies, and allowed analysis of confounders and
interactions [64].
Implications and Generalizability
The validity and generalizability of these findings are supported
by a large number and proportion of patients included in the
analysis. Less than 10% of patients were excluded from the
multivariable analysis. Distribution of the length of folate
supplementation in the excluded pregnancies was similar to that
observed in the study population. Moreover, the study population
is a good representation of a general US population [65]. The
incidence of early preterm birth the main outcome of the study is
1.5% in the general population and 1.4% in the study population
[1]. There was no significant association between preconceptional
folate supplementation and duration of pregnancy, because early
spontaneous preterm birth contributes only a very small fraction to
the duration of pregnancy. Univariate association with the birth
weight is likley a result of confounding by risk factors for fetal
growth restriction, because the association was eliminated after
adjustment for maternal characteristics.
We have shown that preconceptional folate supplementation is
associated with a 50%–70% reduction in the incidence of early
spontaneous preterm birth. These findings, despite their limita-
tions, provide a basis for further inquiry into preconceptional
folate supplementation for prevention of spontaneous preterm
birth in clinical trials.
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Table S1 Risk of spontaneous preterm birth and
preconceptional folate supplementation: Results of
maximum likelihood and exact models. Definitions: No
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from Cox regression with Breslow assumption maximum likeli-
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(incidence rate ratio) 95% CI, from exact Poisson regression.
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Background. Most pregnancies last about 40 weeks, but
sometimes the new family member arrives early. Every year,
half a million babies in the United States (12.5% of all babies)
are born prematurely (before 37 completed weeks of
pregnancy). Sadly, premature babies are more likely to die
than full-term babies and many have short- and/or long-term
health problems. Premature babies often have breathing
problems, they are susceptible to life-threatening infections,
and they are more likely to have learning and developmental
disabilities than those born on time. The severity of these
health problems depends on the degree of prematurity—
preterm babies born between 34 and 36 weeks of pregnancy
rarely develop severe disabilities, but a quarter of babies
born before 28 weeks of pregnancy develop serious lasting
disabilities and half have learning and behavioral problems.
Although doctors have identified some risk factors for early
delivery (for example, smoking), it is impossible to predict
who will have an early birth and there is no effective way to
prevent preterm births.
Why Was This Study Done? Some researchers think that
folate supplements may prevent preterm births. Folate (folic
acid), a vitamin found in leafy green vegetables, fruits, and
dried beans, helps to prevent neural tube birth defects.
Consequently, women are encouraged to take folic acid
supplements throughout (and preferably before) pregnancy
and many governments now mandate that bread, pasta, and
other grain products be fortified with folic acid to help
women get sufficient folate. There is some evidence that
women who deliver early have less folate in their blood than
women who deliver at term. Furthermore, folate
supplementation during pregnancy has increased the
length of pregnancy in some but not all clinical trials. A
possible explanation for these mixed results is that the
duration of pregnancy reflects conditions in the earliest
stages of pregnancy or before conception and that folate
supplementation needs to start before conception to reduce
the risk of preterm birth. In this study, the researchers test
this idea by analyzing data collected from nearly 35,000
pregnant women enrolled in a study that was originally
designed to investigate screening for Down’s syndrome.
What Did the Researchers Do and Find? During the first
three months of their pregnancy, the women were asked
whether they had taken folate supplements before
conception. The duration of each pregnancy was estimated
from ultrasound measurements taken early in the pregnancy
and from the time of delivery. During the study, 1,658
women had spontaneous preterm deliveries before 37 weeks
and 160 delivered before 32 weeks. After allowing for other
maternal characteristics that might have affected the
likelihood of preterm delivery, the risk of spontaneous
preterm delivery between 20 and 28 weeks was 70% lower in
women who took folate supplements for more than a year
before becoming pregnant than in women who didn’t take a
supplement. Long-term folate supplementation also reduced
the risk of preterm delivery between 28 and 32 weeks by
50% but did not affect the risk of preterm birth beyond 32
weeks. Folate supplementation for less than a year before
conception did not reduce the risk of preterm birth, and
folate supplementation was not associated with any other
complications of pregnancy.
What Do These Findings Mean? These findings show
that folate supplementation for a year or more before
conception is associated with a 50%–70% decrease in early
(but not late) spontaneous preterm births and that the
longer a woman takes folate supplements before becoming
pregnant, the lower her risk of a preterm birth. Although the
researchers allowed for maternal characteristics that might
have affected the duration of pregnancy, it is possible that
folate supplementation may not be responsible for the
reduction in preterm birth risk seen in this study. For
example, taking folate supplements may be a marker of
healthy behavior and the women taking the supplements
might have been doing something else that was reducing
their risk of preterm birth. However, despite this and other
limitations of this study, these findings suggest that long-
term folate supplementation before conception is worth
investigating further as a potential way to prevent preterm
births.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000061.
N This study is further discussed in a PLoS Medicine
Perspective by Nicholas Fisk
N The MedlinePlus encyclopedia contains a page on
premature babies (in English and Spanish); MedlinePlus
provides links to other information on premature babies
(in English and Spanish)
N The US National Institute of Child Health and Human
Development provides information on preterm labor and
birth
N The March of Dimes, a nonprofit organization for
pregnancy and baby health, provides information on
preterm birth and on folic acid (in English and Spanish)
N The Nemours Foundation, another nonprofit organization
for child health, also provides information on premature
babies (in English and Spanish)
N The US Office of Dietary Supplements has a fact sheet on
folate
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